NBIX News and Press, Neurocrine Biosciences Inc. From 08/28/23

2023-08-28 10:50:19 ET More on Neurocrine Biosciences Neurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do It Neurocrine Biosciences: Ingrezza Impresses Amid Costly Pipeline Expansion Efforts BMO upgrades Neurocrine to market perform on ...

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease PR Newswire Data Presented at the 2023 MDS International Congress of Parkinson's Disease and Movement Diso...

2023-08-18 17:35:35 ET More on Neurocrine Neurocrine Biosciences: Ingrezza Impresses Amid Costly Pipeline Expansion Efforts Neurocrine Biosciences, Inc. ( NBIX ) Q2 2023 Earnings Call Transcript Neurocrine Biosciences: In Limbo Until The Arrival Of The 'Next Big ...

2023-08-18 17:34:51 ET More on Neurocrine Biosciences Neurocrine Biosciences: Ingrezza Impresses Amid Costly Pipeline Expansion Efforts Neurocrine Biosciences, Inc. 2023 Q2 - Results - Earnings Call Presentation Neurocrine Biosciences, Inc. ( NBIX ) Q2 2023 Earni...

Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease PR Newswire SAN DIEGO , Aug. 18, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc . (Nasdaq: NBIX) ...

2023-08-18 15:00:03 ET More on the market Jackson Hole: Fed Faces Ghosts Of 1970s As Stock Market Rollercoaster Continues Resolving An Overbought Condition For The Stock Market Dollar Bulls Still In Control Why I Stopped Buying The S&P 500 To Buy REITs Inst...

2023-08-11 15:00:30 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

2023-08-04 03:08:41 ET Summary Neurocrine Biosciences' Q2 2023 performance showed 26% growth in Ingrezza sales, improvement in net income, and a stable financial position. Despite growth, challenges persist with high operational costs, overvaluation concerns, and uncertainty in di...

2023-08-01 14:08:09 ET Neurocrine Biosciences, Inc. (NBIX) Q2 2023 Earnings Conference Call August 01, 2023, 08:00 AM ET Company Participants Todd Tushla - VP, IR Kevin Gorman - CEO Matt Abernethy - CFO Eiry Roberts - Chief Medical Officer Eric Benevich -...

2023-08-01 07:18:53 ET Neurocrine Biosciences press release ( NASDAQ: NBIX ): Q2 Non-GAAP EPS of $1.25 beats by $0.13 . Revenue of $452.7M (+19.7% Y/Y) beats by $4.72M . INGREZZA (valbenazine) Second Quarter Net Product Sales of $440 Million Representing...